参考文献/References:
[1] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志,2022,37(6):553-578.
[2] Giustino G,Colombo A,Camaj A,et al. Coronary in-stent restenosis:JACC state-of-the-art review[J]. J Am Coll Cardiol,2022,80(4):348-372.
[3] Liu Y,Xiao D,Wu Y,et al. Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction:A systematic review and meta-analysis of randomized clinical trials[J]. Front Cardiovasc Med,2022,9:974957.
[4] Jinnouchi H,Torii S,Sakamoto A,et al. Fully bioresorbable vascular scaffolds:lessons learned and future directions[J]. Nat Rev Cardiol,2019,16(5):286-304.
[5] Byrne RA,Alfonso F,Schneider S,et al. Prospective,randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction:the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial[J]. Eur Heart J,2019,40(2):167-176.
[6] Kereiakes DJ,Ellis SG,Metzger DC,et al. Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption:five-year follow-up from the ABSORB Ⅲ trial[J]. Circulation,2019,140(23):1895-1903.
[7] R?ber L,Yamaji K,Kelb?k H,et al. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial:randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction[J]. Eur Heart J,2019,40(24):1909-1919.
[8] Gomez‐Lara J,Oyarzabal L,Ortega‐Paz L,et al. Coronary endothelium‐dependent vasomotor function after drug‐eluting stent and bioresorbable scaffold implantation[J]. J Am Heart Assoc,2021,10(22):e022123.
[9] Omar WA,Kumbhani DJ. The current literature on bioabsorbable stents:a review[J]. Curr Atheroscler Rep,2019,21(12):54.
[10] Sotomi Y,Suwannasom P,Serruys PW,et al. Possible mechanical causes of scaffold thrombosis:insights from case reports with intracoronary imaging[J]. EuroIntervention,2017,12(14):1747-1756.
[11] Timmers L,Stella PR,Agostoni P. Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy[J]. Eur Heart J,2015, 36(6):393.
[12] Campos CM,Caixeta A,Franken M,et al. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent:2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.[J]. Catheter Cardiovasc Interv,2018,91(3):387-395.
[13] Ali ZA,Serruys PW,Kimura T,et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease:a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy[J]. Lancet,2017,390(10096):760-772.
[14] Yamaji K,Ueki Y,Souteyrand G,et al. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis:the INVEST registry[J]. J Am Coll Cardiol,2017,70(19):2330-2344.
[15] Serruys PW,Chevalier B,Dudek D,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB Ⅱ):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial[J]. Lancet,2015,385(9962):43-54.
[16] Stone GW,Abizaid A,Onuma Y,et al. Effect of technique on outcomes following bioresorbable vascular scaffold implantation:analysis from the ABSORB trials[J]. J Am Coll Cardiol,2017,70(23):2863-2874.
[17] Otsuka F,Pacheco E,Perkins LE,et al. Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model[J]. Circ Cardiovasc Interv,2014,7(3):330-342.
[18] Xu B,Yang Y,Han Y,et al. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents:three-year clinical outcomes from the ABSORB China randomised trial[J]. EuroIntervention,2018,14(5):e554-e561.
[19] Gallinoro E,Almendarez M,Alvarez-Velasco R,et al. Bioresorbable stents:Is the game over?[J]. Int J Cardiol,2022,361:20-28.
[20] Masiero G, Rodinò G, Matsuda J, et al. Bioresorbable Coronary Scaffold Technologies[J]. Cardiol Clin, 2020, 38(4):589-599.
[21] Stone GW,Kimura T,Gao R,et al. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up:a systematic meta-analysis and individual patient data pooled study[J]. JAMA Cardiol,2019,4(12):1261-1269.
[22] Felix C, Vlachojannis G, IJsselmuiden A, et al. Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months[J]. EuroIntervention,2017,13(2):e177-e184.
[23] Azzalini L,Ellis SG,Kereiakes DJ,et al. Optimal dual antiplatelet therapy duration for bioresorbable scaffolds:an individual patient data pooled analysis of the ABSORB trials[J]. EuroIntervention,2021,17(12):e981-e988.
[24] Kerkmeijer LKM,Renkens MRL,Tijssen RYG,et al. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents:final five-year results of the AIDA randomised clinical trial[J]. EuroIntervention,2022,17(16):1340-1347.
[25] Han Y,Xu B,Fu G,et al. A randomized trial comparing the neovas sirolimus-eluting bioresorbable scaffold and metallic everolimus-eluting stents[J]. JACC Cardiovasc Interv,2018,11(3):260-272.
[26] Wang X,Li Y,Fu G,et al. Three‐year clinical outcomes of the novel sirolimus‐eluting bioresorbable scaffold for the treatment of de novo coronary artery disease:A prospective patient‐level pooled analysis of NeoVas trials[J]. Catheter Cardio Interv,2023,101(6):967-972.
[27] Wu Y,Yin J,Chen J,et al. Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study[J]. Ann Transl Med,2020,8(18):1162.
[28] Wu Y,Yao Z,Yin J,et al. Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis[J]. Ann Transl Med,2020,8(22):1489.
[29] Song L,Sun Z,Guan C,et al. First‐in‐man study of a thinner‐strut sirolimus‐eluting bioresorbable scaffold (FUTURE‐I):Three‐year clinical and imaging outcomes[J]. Catheter Cardio Inte,2020,95Suppl 1:648-657.
[30] Song L,Xu B,Chen Y,et al. Thinner strut sirolimus-eluting brs versus EES in patients with coronary artery disease[J]. JACC Cardiovasc Interv,2021,14(13):1450-1462.
[31] Chevalier B,Abizaid A,Carrié D,et al. Clinical and angiographic outcomes with a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold[J]. Circ Cardiovasc Interv,2019,12(6):e007283.
[32] Koltowski L,Tomaniak M,Ochijewicz D,et al. Third-generation sirolimus‐eluting bioresorbable tyrocore scaffold implantation in patients with ST‐segment elevation myocardial infarction:baseline and 6-month OCT and clinical outcomes-a FANTOM STEMI pilot study[J]. Cardiovasc Drug Ther,2023,doi:10.1007/s10557-023-07429-0. Online ahead of print.
[33] Wlodarczak A,Lanocha M,Jastrzebski A,et al. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris‐ACS registry[J]. Catheter Cardiovasc Interv,2019,93(5):E287-E292.
[34] Verheye S,Wlodarczak A,Montorsi P,et al. BIOSOLVE‐IV‐registry:Safety and performance of the Magmaris scaffold:12‐month outcomes of the first cohort of 1,075 patients[J]. Catheter Cardiovasc Interv,2021,98(1):E1-E8.
[35] Ortega-Paz L,Brugaletta S,Gomez-Lara J,et al. Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction:3-year results of the MAGSTEMI randomised controlled trial[J]. EuroIntervention,2022,18(5):e389-e396.
[36] Gao RL,Xu B,Sun Z,et al. First-in-human evaluation of a novel ultrathin sirolimus-eluting iron bioresorbable scaffold:3-year outcomes of the IBS-FIM trial[J]. EuroIntervention,2023,EIJ-D-22-00919. doi: 10.4244/EIJ-D-22-00919. Online ahead of print.
相似文献/References:
[1]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(7):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[2]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[3]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[4]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(7):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(7):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[6]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(7):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[7]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(7):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[8]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(7):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[9]宋艳华 来春林 杨五小.急性 ST段抬高型心肌梗死患者微血管功能障碍的研究进展[J].心血管病学进展,2022,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
SONG Yanhua,LAI Chunlin,YANG Wuxiao.Microvascular Dysfunction in Patients with Acute ST-Segment?levation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(7):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
[10]纪欣强 王凡.肥胖悖论与经皮冠状动脉介入治疗预后相关性的研究进展[J].心血管病学进展,2022,(7):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
JI XinqiangWANG Fan.Correlation Between Obesity Paradox and Prognosis of Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(7):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]